A man has been charged with contaminating tablets of Nurofen Plus, which were recalled by manufacturer Reckitt Benckiser last month.

Christopher McGuire, from London, was charged with one count of contaminating goods and two of administering a noxious substance before Westminster Magistrates, reports BBC news.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Four of packs of painkiller Nurofen Plus, sold over the counter in the UK were found to contain AstraZenca’s Seroquel XL antipsychotic drugs in August.

A pack containing prescription medicine for epilepsy, Pfizer’s Neurontin, in 100mg capsules, was also discovered in Northern Ireland.

The Medicines and Healthcare products Regulatory Agency began investigations immediately into how the drugs came into contact with Nurofen Plus.

AstraZenca said in a statement in August, "Seroquel XL tablets and Nurofen are made by two different companies [AstraZeneca and Reckitt Benckiser] and are not manufactured or packaged in the same factory. Manufacturing errors by Reckitt Benckiser and AstraZeneca are not considered to be part of the cause at this stage."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact